Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
RESEARCH TOOLSreports
MDNAF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $2.20
Previous CloseN/A
Volume34.40K
Average Volume (3M)73.05K
Market Cap
C$54.77M
Enterprise Value$114.97M
Total Cash (Recent Filing)C$30.00M
Total Debt (Recent Filing)C$174.00K
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Jun 25, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding78,215,750
10 Day Avg. Volume55,227
30 Day Avg. Volume73,053
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside267.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Medicenna Therapeutics Corp News
PremiumCompany Announcements
Medicenna to Present Key Updates at AACR 2025
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promising Results in Cancer Treatment
PremiumCompany Announcements
Medicenna to Engage Investors at February 2025 Conferences
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promise in Cancer Treatment
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promising Cancer Treatment Results
PremiumCompany Announcements
Medicenna Unveils New Data on Cancer Treatment---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEncouraging responses were observed in the combination arm for patients who do not typically benefit from immunotherapy.
Financial StabilityThe cash runway for Medicenna Therapeutics extends into mid-calendar 2026, supporting its financial stability.
Bears Say
Efficacy ConcernsIt is still too early to determine the efficacy of the combo data, necessitating further investigation.
Response RateThe overall response rate (ORR) for the Medicenna pembro combo in solid tumors is low at 22%.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.17% Insiders
0.15% Other Institutional Investors
84.68% Public Companies and
Individual Investors
MDNAF FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was $0.61 and its highest was $2.20 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is C$54.77M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 25, 2025 which is in 89 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Feb 13, 2025. The company reported -$0.049 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.005.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -0.03.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 78,215,750 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -$0.049 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in MDNAF
---
Medicenna Therapeutics Corp Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (267.99% Upside)
$2.50 (267.99% Upside)
Blogger Sentiment
Bullish
MDNAF Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth C$121.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.48%
12-Months-Change
Fundamentals
Return on Equity
-149.09%
Trailing 12-Months
Asset Growth
38.55%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
---
MDNAF Stock 12 Month Forecast
Average Price Target
$2.50
▲(267.99% Upside)
Technical Analysis
Best Analysts Covering MDNAF
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
+29.03%
reiterated a buy rating 4 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +29.03% per trade.
---